Does the media refer more to LFCR or SGP?

In the previous week, Lifecore Biomedical had 4 more articles in the media than Spyglass Pharma. MarketBeat recorded 7 mentions for Lifecore Biomedical and 3 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 0.59 beat Lifecore Biomedical's score of -0.04 indicating that Spyglass Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARDX or LFCR?

In the previous week, Ardelyx had 16 more articles in the media than Lifecore Biomedical. MarketBeat recorded 23 mentions for Ardelyx and 7 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of -0.04 beat Ardelyx's score of -0.05 indicating that Lifecore Biomedical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GYRE or LFCR?

Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 0.78%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts clearly believe Lifecore Biomedical is more favorable than Gyre Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gyre Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Lifecore Biomedical 1 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.80

Does the media refer more to GYRE or LFCR?

In the previous week, Lifecore Biomedical had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Lifecore Biomedical and 4 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.53 beat Lifecore Biomedical's score of -0.04 indicating that Gyre Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gyre Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer LFCR or ACHV?

In the previous week, Lifecore Biomedical had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 7 mentions for Lifecore Biomedical and 5 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.59 beat Lifecore Biomedical's score of -0.04 indicating that Achieve Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lifecore Biomedical 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Achieve Life Sciences 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lifecore Biomedical (LFCR) Competitors

$6.45 +0.02 (+0.31%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$6.44 0.00 (-0.08%)

As of 10/9/2026 04:38 PM Eastern

Compare

LFCR vs. TBPH, SGP, ARDX, GYRE, and ACHV

Should you buy Lifecore Biomedical stock or one of its competitors? Lifecore Biomedical's main competitors and comparable companies include Theravance Biopharma (TBPH), Spyglass Pharma (SGP), Ardelyx (ARDX), Gyre Therapeutics (GYRE), and Achieve Life Sciences (ACHV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Lifecore Biomedical compare to Theravance Biopharma?

Lifecore Biomedical (NASDAQ:LFCR) and Theravance Biopharma (NASDAQ:TBPH) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Theravance Biopharma has a net margin of 51.58% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Theravance Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Theravance Biopharma	51.58%	-0.77%	-0.46%

Lifecore Biomedical has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market. Comparatively, Theravance Biopharma has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market.

83.4% of Lifecore Biomedical shares are held by institutional investors. Comparatively, 99.1% of Theravance Biopharma shares are held by institutional investors. 32.7% of Lifecore Biomedical shares are held by company insiders. Comparatively, 7.7% of Theravance Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Lifecore Biomedical currently has a consensus price target of $6.50, suggesting a potential upside of 0.78%. Theravance Biopharma has a consensus price target of $19.40, suggesting a potential upside of 13.92%. Given Theravance Biopharma's stronger consensus rating and higher possible upside, analysts clearly believe Theravance Biopharma is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Theravance Biopharma	0 Sell rating(s)	8 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Theravance Biopharma has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Theravance Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.89	-$40.50M	-$1.07	N/A
Theravance Biopharma	$104.31M	8.48	$105.89M	$1.01	16.86

In the previous week, Lifecore Biomedical had 7 more articles in the media than Theravance Biopharma. MarketBeat recorded 7 mentions for Lifecore Biomedical and 0 mentions for Theravance Biopharma. Theravance Biopharma's average media sentiment score of 0.00 beat Lifecore Biomedical's score of -0.04 indicating that Theravance Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Lifecore Biomedical	Neutral
Theravance Biopharma	Neutral

Summary

Theravance Biopharma beats Lifecore Biomedical on 10 of the 15 factors compared between the two stocks.

How does Lifecore Biomedical compare to Spyglass Pharma?

Lifecore Biomedical (NASDAQ:LFCR) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

In the previous week, Lifecore Biomedical had 4 more articles in the media than Spyglass Pharma. MarketBeat recorded 7 mentions for Lifecore Biomedical and 3 mentions for Spyglass Pharma. Spyglass Pharma's average media sentiment score of 0.59 beat Lifecore Biomedical's score of -0.04 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyglass Pharma has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Spyglass Pharma	N/A	-62.40%	-24.83%

Lifecore Biomedical currently has a consensus target price of $6.50, indicating a potential upside of 0.78%. Spyglass Pharma has a consensus target price of $44.00, indicating a potential upside of 76.57%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

83.4% of Lifecore Biomedical shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Spyglass Pharma has lower revenue, but higher earnings than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.89	-$40.50M	-$1.07	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Summary

Lifecore Biomedical and Spyglass Pharma tied by winning 7 of the 14 factors compared between the two stocks.

How does Lifecore Biomedical compare to Ardelyx?

Ardelyx (NASDAQ:ARDX) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Ardelyx has a net margin of -12.35% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Ardelyx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ardelyx	-12.35%	-36.00%	-10.77%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Ardelyx currently has a consensus target price of $13.90, indicating a potential upside of 323.78%. Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 0.78%. Given Ardelyx's stronger consensus rating and higher possible upside, research analysts plainly believe Ardelyx is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

In the previous week, Ardelyx had 16 more articles in the media than Lifecore Biomedical. MarketBeat recorded 23 mentions for Ardelyx and 7 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of -0.04 beat Ardelyx's score of -0.05 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.9% of Ardelyx shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 5.3% of Ardelyx shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Ardelyx has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 0.98, meaning that its stock price is 2% less volatile than the broader market.

Lifecore Biomedical has lower revenue, but higher earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ardelyx	$407.32M	2.01	-$61.60M	-$0.22	N/A
Lifecore Biomedical	$128.87M	1.89	-$40.50M	-$1.07	N/A

Summary

Ardelyx beats Lifecore Biomedical on 10 of the 17 factors compared between the two stocks.

How does Lifecore Biomedical compare to Gyre Therapeutics?

Gyre Therapeutics (NASDAQ:GYRE) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, media sentiment, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

24.0% of Gyre Therapeutics shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 9.5% of Gyre Therapeutics shares are held by insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Gyre Therapeutics has higher earnings, but lower revenue than Lifecore Biomedical. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Lifecore Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gyre Therapeutics	$116.59M	6.73	$5.03M	-$0.21	N/A
Lifecore Biomedical	$128.87M	1.89	-$40.50M	-$1.07	N/A

In the previous week, Lifecore Biomedical had 3 more articles in the media than Gyre Therapeutics. MarketBeat recorded 7 mentions for Lifecore Biomedical and 4 mentions for Gyre Therapeutics. Gyre Therapeutics' average media sentiment score of 0.53 beat Lifecore Biomedical's score of -0.04 indicating that Gyre Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gyre Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gyre Therapeutics has a beta of 1.89, indicating that its stock price is 89% more volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 0.98, indicating that its stock price is 2% less volatile than the broader market.

Gyre Therapeutics has a net margin of -15.47% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Gyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gyre Therapeutics	-15.47%	-6.57%	-5.35%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Lifecore Biomedical has a consensus price target of $6.50, indicating a potential upside of 0.78%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, analysts clearly believe Lifecore Biomedical is more favorable than Gyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gyre Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80

Summary

Lifecore Biomedical beats Gyre Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lifecore Biomedical compare to Achieve Life Sciences?

Lifecore Biomedical (NASDAQ:LFCR) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and valuation.

Lifecore Biomedical has higher revenue and earnings than Achieve Life Sciences. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.89	-$40.50M	-$1.07	N/A
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A

Lifecore Biomedical presently has a consensus target price of $6.50, indicating a potential upside of 0.78%. Achieve Life Sciences has a consensus target price of $15.50, indicating a potential upside of 109.18%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Lifecore Biomedical had 2 more articles in the media than Achieve Life Sciences. MarketBeat recorded 7 mentions for Lifecore Biomedical and 5 mentions for Achieve Life Sciences. Achieve Life Sciences' average media sentiment score of 0.59 beat Lifecore Biomedical's score of -0.04 indicating that Achieve Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lifecore Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Achieve Life Sciences	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lifecore Biomedical has a beta of 0.98, suggesting that its share price is 2% less volatile than the broader market. Comparatively, Achieve Life Sciences has a beta of 2.3, suggesting that its share price is 130% more volatile than the broader market.

Achieve Life Sciences has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Achieve Life Sciences	N/A	-511.12%	-82.35%

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 1.8% of Achieve Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Lifecore Biomedical and Achieve Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

Get Lifecore Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LFCR vs. The Competition

Export

Metric	Lifecore Biomedical	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$243.40M	$12.32B	$7.16B	$13.21B
Dividend Yield	N/A	2.64%	2.53%	16.37%
P/E Ratio	-6.03	797.58	274.15	26.16
Price / Sales	1.89	939.81	635.97	113.01
Price / Cash	N/A	85.97	76.38	53.09
Price / Book	15.36	10.71	11.21	6.34
Net Income	N/A	$2.84B	$3.50B	$381.90M
7 Day Performance	-1.38%	-0.93%	-0.90%	-1.41%
1 Month Performance	57.70%	-4.91%	-4.44%	-3.48%
1 Year Performance	-0.77%	-4.13%	6.96%	1.16%

Lifecore Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LFCR Lifecore Biomedical	1.1711 of 5 stars	$6.45 +0.3%	$6.50 +0.8%	-2.7%	$243.40M	$128.87M	N/A	382
TBPH Theravance Biopharma	1.8101 of 5 stars	$17.03 flat	$19.40 +13.9%	N/A	$884.18M	$104.31M	16.86	90
SGP Spyglass Pharma	3.1516 of 5 stars	$25.44 -2.1%	$44.00 +73.0%	N/A	$868.60M	N/A	N/A	65
ARDX Ardelyx	2.8426 of 5 stars	$3.39 -0.6%	$13.90 +310.0%	-35.2%	$849.73M	$407.32M	N/A	489	Trending News Options Volume
GYRE Gyre Therapeutics	0.9233 of 5 stars	$7.32 -2.3%	$16.00 +118.6%	-1.5%	$835.21M	$116.59M	N/A	618	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LFCR) was last updated on 10/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lifecore Biomedical (LFCR) Competitors

LFCR vs. TBPH, SGP, ARDX, GYRE, and ACHV

How does Lifecore Biomedical compare to Theravance Biopharma?

Summary

How does Lifecore Biomedical compare to Spyglass Pharma?

Summary

How does Lifecore Biomedical compare to Ardelyx?

Summary

How does Lifecore Biomedical compare to Gyre Therapeutics?

Summary

How does Lifecore Biomedical compare to Achieve Life Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lifecore Biomedical (LFCR) Competitors

LFCR vs. TBPH, SGP, ARDX, GYRE, and ACHV

How does Lifecore Biomedical compare to Theravance Biopharma?

Is LFCR or TBPH more profitable?

Which has more risk and volatility, LFCR or TBPH?

Do insiders & institutionals have more ownership in LFCR or TBPH?

Do analysts prefer LFCR or TBPH?

Which has preferable earnings and valuation, LFCR or TBPH?

Does the media refer more to LFCR or TBPH?

Summary

How does Lifecore Biomedical compare to Spyglass Pharma?

Does the media refer more to LFCR or SGP?

Is LFCR or SGP more profitable?

Do analysts recommend LFCR or SGP?

Do institutionals and insiders believe in LFCR or SGP?

Which has stronger earnings and valuation, LFCR or SGP?

Summary

How does Lifecore Biomedical compare to Ardelyx?

Is ARDX or LFCR more profitable?

Do analysts recommend ARDX or LFCR?

Does the media refer more to ARDX or LFCR?

Do insiders & institutionals hold more shares of ARDX or LFCR?

Which has more risk & volatility, ARDX or LFCR?

Which has better valuation & earnings, ARDX or LFCR?

Summary

How does Lifecore Biomedical compare to Gyre Therapeutics?

Do institutionals and insiders believe in GYRE or LFCR?

Which has preferable earnings & valuation, GYRE or LFCR?

Does the media refer more to GYRE or LFCR?

Which has more volatility & risk, GYRE or LFCR?

Is GYRE or LFCR more profitable?

Do analysts recommend GYRE or LFCR?

Summary

How does Lifecore Biomedical compare to Achieve Life Sciences?

Which has stronger earnings and valuation, LFCR or ACHV?

Do analysts rate LFCR or ACHV?

Does the media prefer LFCR or ACHV?

Which has more volatility & risk, LFCR or ACHV?

Is LFCR or ACHV more profitable?

Do institutionals & insiders believe in LFCR or ACHV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LFCR vs. The Competition

Lifecore Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools